Recent 8-K filings for ANNX

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon Q1 net loss $44.1M ($0.23/sh); cash $225M; GA Ph3 data Q4 2026

  Net loss $44.1M (-$0.23/sh) vs $54.4M (-$0.37/sh) Q1 2025; R&D $35.8M, G&A $10.3M.

• March 30, 2026, 7:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026

  Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.

• February 17, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02

  Chairman Thomas G. Wiggans to retire from Annexon board at 2026 annual meeting

  Mr. Wiggans notified the Board on Feb 12, 2026 of his intent to retire and not stand for reelection.

• January 14, 2026, 6:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  Annexon furnishes updated corporate presentation with no specific material changes disclosed

  Company updated its corporate presentation for use at the 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected

  Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.

• November 14, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Annexon closes $86.25M public offering of common stock and pre-funded warrants

  Priced 25,096,153 shares at $2.60/share and 3,750,000 pre-funded warrants at $2.599 each.

• November 10, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026

  Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.

• August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026

  Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.

• June 25, 2025, 7:59 PM ET other material materiality 0.55 neutral item 3.03item 9.01

  Annexon extends 2022 common warrants to June 2026, cash exercise only at $5.806875

  Warrants exercisable for up to 6,877,622 shares of common stock.

• June 9, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Annexon stockholders elect Class II directors and ratify auditor at 2025 annual meeting

  Class II directors Jung E. Choi and William D. Waddill elected with 83,207,282 and 62,741,842 votes for, respectively.

• May 12, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing

  Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.

• March 3, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD

  Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.

• January 13, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025

  ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.

• January 10, 2025, 6:59 PM ET leadership materiality 0.60 positive item 5.02item 7.01item 9.01 ◈ executive_change

  Annexon appoints commercial executive William 'BJ' Jones to board of directors

  William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.

• December 16, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE

  ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).

• November 14, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025

  Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.

• October 22, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham

  ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).

• August 12, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026

  Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.

• August 5, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection

  Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).

• June 25, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster

  Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).

• June 12, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  Annexon stockholders elect Class I directors, ratify KPMG, and approve say-on-pay at 2024 Annual Meeting

  Elected William H. Carson, M.D. (78,919,065 for, 597,431 withheld) and Muneer A. Satter (60,965,423 for, 18,551,073 withheld) as Class I directors.

• June 7, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Annexon prices $125M public offering of common stock and pre-funded warrants

  Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.

• June 4, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Annexon Phase 3 GBS trial meets primary endpoint; ANX005 shows 2.4-fold improvement on GBS-DS at week 8

  Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).

• May 13, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024

  Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.

• May 7, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024

  ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.

• March 26, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon reports Q4 2023 net loss $27.9M; cash $259.7M; Phase 3 GBS data Q2 2024

  Net loss for FY2023 $134.2M vs $141.9M in prior year; R&D spend $113.8M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

10 positive 0 negative 16 neutral

source · ANNX on sec.gov